Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-in-class treatments for ocular disease. Aerpioâs lead product candidate, AKB-9778, a small molecule activator of the Tie-2 pathway, is being developed for the treatment of non-proliferative diabetic retinopathy. In contrast to marketed treatments for non-proliferative diabetic retinopathy that are administered by a physician via intraocular injection, AKB-9778 is delivered systemically by self-administered subcutaneous injection. We believe this delivery method provides an opportunity to treat patients at an earlier stage of disease, potentially reducing the likelihood of these patients developing vision-threatening complications. Source
No articles found.
Axovant is accelerating the development of innovative gene therapy products that a...
Axovant is accelerating the development of inno...
Founded in 2006 and headquartered in San Diego, Adamis (ADMP) is a specialty bioph...
Founded in 2006 and headquartered in San Diego,...
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on a...
Concert Pharmaceuticals is a clinical stage bio...
Vivoo is a wellness assistant that consists of urinalysis test strips and a mobile...
Vivoo is a wellness assistant that consists of ...
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based, vertically integrate...
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a Sa...
Beyond Air Inc. is a clinical-stage medical device and biopharmaceutical company d...
Beyond Air Inc. is a clinical-stage medical dev...
Generex Biotechnology is an integrated healthcare holding company with end-to-end ...
Generex Biotechnology is an integrated healthca...
Join the National Investor Network and get the latest information with your interests in mind.